Journal
CURRENT PHARMACEUTICAL DESIGN
Volume 14, Issue 28, Pages 2974-2982Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138161208786404353
Keywords
-
Categories
Funding
- NIH [EB000898]
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000898] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The early assessment of a solid tumor's response to conventional or new drug therapy to complement or replace current RECIST (or other clinical) criteria remains an elusive goal. The work horse PET tracer F-18-FDG, may represent the most immediate method to track individual tumor response to therapy for many types of cancer. Newer radiotracers such as radiolabeled annexin V, have also shown the ability to selectively localize to tumor cells undergoing apoptosis (programmed cell death) in response to successful treatment in vivo. In this article we will review therapy reduced tumor apoptosis and the radiotracers used to date to image this process in both animal models and clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available